

Date: 03/04/2025

To

BSE Limited
Dept. of Corporate Services,
Floor 25, PJ Towers,
Dalal Street, Mumbai-400001

Scrip Code: 526445

Dear Sir/Madam,

Sub.: Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

This is to inform that:

1. The Board of Directors in its meeting held on November 14, 2024 approved the issue of fully paid-up Equity shares by way of Right issue for an amount not exceeding Rs 49.90 Crores. In this regard, the Board has considered and approved the amendments of terms of issue of partly paid-up equity shares instead of fully paid up equity shares as approved by the Board in its meeting held on April 3, 2025, by way of a right issue to the existing shareholders of the Company in accordance with the provisions of the Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws for an amount not exceeding 49.90 Crores (Rupees Forty Nine Crores and Ninety Lakhs).

For the purposes of giving effect to the Rights Issue, the Board has constituted and authorized the Right Issue Committee to decide the terms and conditions of the Right Issue, including the amount, instrument, issue price, rights entitlement ratio, record date, timing of the Right issue and other related matters. Details as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 and SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023, is given below in Annexure A.

2. Vinayaka Bodala, Chief Financial Officer of the Company, tendered his resignation due to personal reasons vide his e-mail dated March 1, 2025. He is relieved from the services of the Company with effect from April 3, 2025. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure B.
3. The Board of Directors, on the recommendation of the Nomination and Remuneration Committee, have approved the appointment of Dhinakaran Rajagopal as the Chief Financial Officer of the Company with effect from April 3, 2025. Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure C.

Please note that in accordance with the Company's Code of Practices and Procedures and Code of Conduct to Regulate, Monitor and Report Trading in Securities and Fair Disclosure of Unpublished Price Sensitive Information (the "Code") read with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for trading in the securities of the Company for Designated Persons and their immediate relatives as intimated earlier shall remain closed till the conclusion of 48 hours after the declaration of financial results of the Company for the quarter and year ended 31st March, 2025 to the Stock Exchange. Accordingly, the trading window shall also be treated as closed for Fund Raising.

The meeting commenced at 3.00 p.m. and concluded at 04:35 p.m.

You are requested to kindly take the above on record.

Thanking you,

Yours faithfully,

For Indrayani Biotech Limited

Swaminathan Govindarajan
Whole-time Director
DIN: 02481041

Encl: as above

ANNEXURE A

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 with respect to the Right issue, are given as under:

Particulars	Details
Type of securities proposed to be issued	Partly paid-up equity shares of face value of Rs.10 each of the Company
Type of issuance (further public offering, rights issue, depository receipts (ADR /GDR), qualified institutions placement, preferential allotment etc.);	Rights issue to the existing shareholders
Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Number of Equity Share and, in such ratio, as may be decided by the Board of Directors/Rights Issue committee for an amount not exceeding Rs 49.90 Crores (Rupees Forty Nine Crores and Ninety Lakhs).
Any cancellation or termination of proposal for issuance of Securities including reasons thereof.	Not applicable

ANNEXURE B

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 with respect to the Resignation of Vinayaka Bodala, as Chief Financial Officer, are given as under:

Sl. No.	Details	Particulars
1	Reason for change viz., (appointment, re-appointment, resignation, removal, death or otherwise)	Vinayaka Bodala, has resigned from his office including from the position of the Chief Financial Officer and Key managerial Personnel (“KMP”)
2	Date of appointment / re- appointment / cessation (as applicable) & terms of appointment / re- appointment	Effective date is April 3, 2025.
3	Brief profile (in case of appointment)	Not Applicable
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

ANNEXURE C

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 with respect to the Appointment of Dhinakaran Rajagopal as Chief Financial Officer, are given as under:

Sl. No.	Details	Particulars
1	Reason for change viz., (appointment, re- appointment, resignation, removal, death or otherwise)	Mr. Dhinakaran Rajagopal has been appointed as Chief Financial Officer and designated as Key Managerial Personnel (“KMP”) of the Company by the Board.
2	Date of appointment / re- appointment / cessation (as applicable) & terms of appointment / re- appointment	April 3, 2025
3	Brief profile (in case of appointment)	<p>Dhinakaran Rajagopal, as the Chief Coordination officer for Indrayani Biotech Limited, oversees multiple key functions within the organisation since 2021. He is also holding position of Non-Executive Director in Vaasan Medical Center (India) Private Limited, a step-down subsidiary of the Company.</p> <p>He has 34 years of experience in various domains across large corporates. He was earlier employed with companies like Infosys Limited in senior managerial position and in top public sector organisations like Bharat Heavy Electricals Limited, Trichy and Indian Oil Corporation Limited, Barauni Refinery.</p> <p>He is an Electrical and Electronics Engineering graduate from SASTRA University (formerly Shanmugha College of Engineering).</p>
4	Disclosure of relationships between directors (in case of appointment of a director)	He is not related to any of the Directors.



swami nathan <gsnathan10@gmail.com>

Resignation from the Position of CFO

Vinayak B <cavinayak.b@gmail.com>
To: swami nathan <gsnathan10@gmail.com>

Sat, 1 Mar at 7:13 AM

Dear Sir,

Due to personal reasons, I am unable to continue working, as continuing would significantly impact my personal life. I am currently in my hometown and will not be able to report to the office.

Please consider this as my formal confirmation that I am unable to continue in my role.

Thanks & Regards,

B Vinayak



[Quoted text hidden]